MedTrace Logo

Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer

NCT01290354 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-11-13

No results posted yet for this study

Summary

The purpose of this study is to find out how much lapatinib can enter both normal brains and brains in which tumours secondary to breast cancer have developed.

Conditions

Interventions

DRUG

Lapatinib

Unlabelled, administered orally

DRUG

[11C] lapatinib

Radiolabelled, administered intravenously

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-12
Primary Completion
2013-03-18
Completion
2013-03-18

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01290354 on ClinicalTrials.gov